S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Options Trading Plan–Perfect For Beginners (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Options Trading Plan–Perfect For Beginners (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Options Trading Plan–Perfect For Beginners (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Options Trading Plan–Perfect For Beginners (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Options Trading Plan–Perfect For Beginners (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Options Trading Plan–Perfect For Beginners (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Options Trading Plan–Perfect For Beginners (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Options Trading Plan–Perfect For Beginners (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:RKDA

Arcadia Biosciences (RKDA) Stock Forecast, Price & News

$3.34
+0.09 (+2.77%)
(As of 09/25/2023 ET)
Compare
Today's Range
$3.25
$3.42
50-Day Range
$3.19
$5.43
52-Week Range
$3.10
$24.00
Volume
3,745 shs
Average Volume
75,954 shs
Market Capitalization
$3.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Arcadia Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
349.1% Upside
$15.00 Price Target
Short Interest
Healthy
0.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$2,382 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($7.27) to ($3.92) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars


RKDA stock logo

About Arcadia Biosciences (NASDAQ:RKDA) Stock

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.

RKDA Price History

RKDA Stock News Headlines

His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Q2 2023 Arcadia Biosciences Inc Earnings Call
Orion (OEC) Misses Q2 Earnings and Revenue Estimates
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
RKDA - Arcadia Biosciences, Inc.
8-K: Arcadia Biosciences, Inc.
Q1 2023 Arcadia Biosciences Inc Earnings Call
Arcadia Biosciences reports Q1 results
See More Headlines
Receive RKDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RKDA Company Calendar

Last Earnings
8/10/2023
Today
9/25/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Agricultural production - crops
Sub-Industry
N/A
Current Symbol
NASDAQ:RKDA
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+349.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,380,000.00
Net Margins
-271.33%
Pretax Margin
-272.78%

Debt

Sales & Book Value

Annual Sales
$9.96 million
Book Value
$33.92 per share

Miscellaneous

Free Float
1,086,000
Market Cap
$3.71 million
Optionable
Not Optionable
Beta
0.98
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Stanley E. Jacot Jr. (Age 53)
    Pres, CEO & Director
    Comp: $527.9k
  • Ms. Laura Pitlik (Age 49)
    Chief Marketing Officer
    Comp: $374k
  • Mr. Thomas J. Schaefer (Age 47)
    CFO & Corp. Sec.
  • Ms. Belinda Yao
    VP of Operations
  • Mr. Brian Schaffer
    Sr. VP of Sales













RKDA Stock - Frequently Asked Questions

Should I buy or sell Arcadia Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RKDA shares.
View RKDA analyst ratings
or view top-rated stocks.

What is Arcadia Biosciences' stock price forecast for 2023?

1 equities research analysts have issued 12-month price objectives for Arcadia Biosciences' shares. Their RKDA share price forecasts range from $10.00 to $20.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 349.1% from the stock's current price.
View analysts price targets for RKDA
or view top-rated stocks among Wall Street analysts.

How have RKDA shares performed in 2023?

Arcadia Biosciences' stock was trading at $0.2710 at the beginning of 2023. Since then, RKDA stock has increased by 1,132.5% and is now trading at $3.34.
View the best growth stocks for 2023 here
.

Are investors shorting Arcadia Biosciences?

Arcadia Biosciences saw a decrease in short interest in August. As of August 31st, there was short interest totaling 600 shares, a decrease of 87.2% from the August 15th total of 4,700 shares. Based on an average daily trading volume, of 38,900 shares, the short-interest ratio is currently 0.0 days. Approximately 0.1% of the company's shares are sold short.
View Arcadia Biosciences' Short Interest
.

When is Arcadia Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our RKDA earnings forecast
.

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences, Inc. (NASDAQ:RKDA) issued its earnings results on Thursday, August, 10th. The basic materials company reported ($2.64) earnings per share for the quarter, beating the consensus estimate of ($4.92) by $2.28. The basic materials company had revenue of $1.39 million for the quarter, compared to the consensus estimate of $1.43 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 69.76% and a negative net margin of 271.33%.

When did Arcadia Biosciences' stock split?

Shares of Arcadia Biosciences reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What guidance has Arcadia Biosciences issued on next quarter's earnings?

Arcadia Biosciences updated its second quarter 2023 earnings guidance on Thursday, July, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.30 million-$1.50 million, compared to the consensus revenue estimate of $1.82 million.

What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO?

1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcadia Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

When did Arcadia Biosciences IPO?

(RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.

What is Arcadia Biosciences' stock symbol?

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

How do I buy shares of Arcadia Biosciences?

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcadia Biosciences' stock price today?

One share of RKDA stock can currently be purchased for approximately $3.34.

How much money does Arcadia Biosciences make?

Arcadia Biosciences (NASDAQ:RKDA) has a market capitalization of $3.71 million and generates $9.96 million in revenue each year. The basic materials company earns $-15,380,000.00 in net income (profit) each year or ($21.36) on an earnings per share basis.

How can I contact Arcadia Biosciences?

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The official website for the company is www.arcadiabio.com. The basic materials company can be reached via phone at (530) 756-7077, via email at ir@arcadiabio.com, or via fax at 530-756-7027.

This page (NASDAQ:RKDA) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -